Bioventus Inc.
BVS
Rank in Stocks
#10030
Bioventus Inc., a medical device company, focuses on relieving pain and... Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Share Price
$11.02
Last synced: 2026-11-09
Market Cap
$754.24M
Change (1 day)
3.82%
Change (1 year)
43.05%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Bioventus Inc. (BVS)
Category
Healthcare
EPS for Bioventus Inc. (BVS)
EPS as of September 2026 TTM: $0.85
According to Bioventus Inc.'s latest financial reports, its current EPS (TTM) is $0.85. At the end of 2025 the company had an EPS of $0.34, an increase over its 2024 EPS of $-0.52.
EPS history for Bioventus Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.85 | 150.00% |
| 2025 | $0.34 | -165.38% |
| 2024 | $-0.52 | -79.12% |
| 2023 | $-2.49 | -3.86% |
| 2022 | $-2.59 | -702.33% |
| 2021 | $0.43 | -2.27% |
| 2020 | $0.44 | 266.67% |
| 2019 | $0.12 | -154.55% |
| 2018 | $-0.22 | 69.23% |
| 2017 | $-0.13 | -68.29% |
| 2016 | $-0.41 | -40.58% |
| 2015 | $-0.69 | 130.00% |
| 2014 | $-0.30 | -36.17% |
| 2013 | $-0.47 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | 217.65% |
US
|
|
| $4.09 | 381.18% |
IE
|
|
| $9.45 | 1,011.76% |
US
|
|
| $2.37 | 178.82% |
US
|
|
| $1.77 | 108.24% |
US
|
Questions about Bioventus Inc.'s earnings per share (EPS)
What is Bioventus Inc.'s earnings per share (EPS)?
Bioventus Inc.'s earnings per share (EPS) over the last twelve months is $0.85, as of Sep 2026.
What was Bioventus Inc.'s earnings per share (EPS) in 2025?
In 2025, Bioventus Inc.'s earnings per share (EPS) was $0.34, compared with $-0.52 in 2024.
How has Bioventus Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Bioventus Inc.'s earnings per share (EPS) went from $0.44 to $0.34, an average decline of 5.03% a year.
How does Bioventus Inc.'s earnings per share (EPS) compare with similar companies?
Bioventus Inc.'s earnings per share (EPS) ($0.85) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.